Records containing: Schizophrenia
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-11-21Effect of Immersive Virtual Reality-based Cognitive Remediation in Patients With Mood Disorders or Psychosis Spectrum Disorders: a Randomized, Controlled, Double-blinded Trial
-
CLINICAL_TRIALS study record update · 2025-11-19A Randomized, Double-Blind, Placebo-Controlled, Dose- Ascending Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Chinese Adult Healthy Subjects and/or Subjects With Stable Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-18Prospective 12-week Randomized Controlled Trial (RCT) of Remotely- Delivered Customized Adherence Enhancement for Poorly Adherent Individuals With Schizophrenia (CAE-S) vs Enhanced Treatment as Usual (eTAU)
-
CLINICAL_TRIALS study record update · 2025-11-18Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
-
CLINICAL_TRIALS study record update · 2025-11-12An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-11-12An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents
-
CLINICAL_TRIALS study record update · 2025-11-12An Open-label Multiple Oral Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lumateperone in Patients, Ages 13 to 17 Years, Diagnosed With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2025-11-12Single-Blind Randomized Ketogenic Diet vs. Control Diet in People With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-05Motivation Skills Training to Enhance Functional Outcomes for People With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-05A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)
-
CLINICAL_TRIALS study record update · 2025-11-05Optimizing Cognitive Behavioral Social Skills Training With Executive Function Training for Older Adults With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-28A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
-
CLINICAL_TRIALS study record update · 2025-10-27A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
-
CLINICAL_TRIALS study record update · 2025-10-22A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Acute Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-20A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period
-
CLINICAL_TRIALS study record update · 2025-10-16A Randomized, Multicenter, 16-week Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-16A Single-Arm, Open Label, 16-week Extension Study to Evaluate the Efficacy and Safety of a Second Course of a Digital Therapeutic as an Adjunct to Standard of Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-15A Multicenter, Pragmatic Study to Evaluate Clinical Effectiveness, Engagement With the Study App, Healthcare Resource Utilization, and Safety of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-15Passive Mobile Self-Tracking of Mental Health by Veterans With Serious Mental Illness
-
CLINICAL_TRIALS study record update · 2025-10-09Acceptability and Feasibility of Work-Oriented, Veteran-Centric, Social-Cognitive Skills Training
-
CLINICAL_TRIALS study record update · 2025-10-08A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-07Does the Addition of Cognitive Remediation to Coordinated Specialty Care Services Improve Functional Outcome
-
CLINICAL_TRIALS study record update · 2025-10-03Remote State Representation in Early Psychosis
-
CLINICAL_TRIALS study record update · 2025-10-03A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-03Efficacy of Social Cognition Training in Schizophrenia